Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FES | P07332 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.45 |
| ▸ | INSR | P06213 | 3/20 | 0.45 |
| ▸ | NPM1 | P06748 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 3/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056958 | 0.86 | FES (0.68) | FESFLT3ALKINSRNPM1 | |
| SCHEMBL23011312 | 0.84 | ALK (0.63) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL22985878 | 0.83 | FES (0.61) | FESFLT3ALKINSRIGF1R | |
| SCHEMBL22985901 | 0.82 | EGFR (0.41) | ALKINSRIGF1RTNK2EGFR | |
| SCHEMBL22985890 | 0.81 | FES (0.60) | FESFLT3ALKINSRIGF1R | |
| SCHEMBL22985900 | 0.80 | FES (0.74) | FESFLT3ALKINSRIGF1R | |
| SCHEMBL22985905 | 0.77 | FES (0.64) | FESFLT3ALKINSRIGF1R | |
| SCHEMBL22985860 | 0.77 | LRRK2 (0.53) | FESFLT3MAPK7 | |
| SCHEMBL12245787 | 0.76 | ALK (0.75) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL22985897 | 0.73 | FES (0.64) | FESFLT3ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |